文献速递间质性肺疾病

52基因风险谱预测特发性肺纤维化结局的国际多中心队列验证

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.
PubMed 文献 · Lancet Respir Med · 2017-09-21

该国际多中心队列研究在6个队列的425例IPF患者中验证外周血52基因表达特征对结局的预测价值。将该风险谱加入GAP指数可显著提高死亡预测准确性。

要点

  • 52基因风险谱可将IPF患者分为低风险和高风险两组,预测死亡和无移植生存。
  • 将52基因风险谱加入GAP指数可显著提高死亡预测准确性。
  • 抗纤维化药物治疗后基因评分变化与FVC改善相关,尚需前瞻性研究验证。

核心结论

  • 外周血52基因表达特征可预测IPF患者的结局。
  • 52基因特征在预测治疗反应方面的潜在价值尚需前瞻性研究确定。

研究设计与样本

  • 国际多中心六队列研究,纳入耶鲁大学、伦敦帝国理工学院、芝加哥大学、匹兹堡大学、弗莱堡大学和布莱根妇女医院-哈佛医学院的IPF患者。
  • 基线采集425例参与者的外周血单核细胞或全血,随访4-6年期间采集98例患者(23%)样本。
  • 52基因特征在四个队列中通过nCounter分析系统检测,在另外两个队列中从微阵列数据(GeneChip)提取。
  • 采用分子亚表型评分算法(SAMS)基于52基因特征将患者分为低风险或高风险组。
  • 采用竞争风险模型研究死亡,采用Cox比例风险模型研究无移植生存,采用线性混合效应模型分析时间过程数据和抗纤维化药物反应。

主要发现

  • 将52基因风险谱加入性别、年龄和生理指数(GAP指数)显著提高其死亡预测准确性。
  • 两个队列中SAMS评分的时间变化与用力肺活量(FVC)变化相关。

临床怎么用

  • 可利用外周血52基因表达特征联合GAP指数对IPF患者进行风险分层,辅助预测死亡和无移植生存。
  • 抗纤维化治疗后的基因评分动态变化可能有助于评估治疗反应,但需前瞻性研究确认。

局限性

  • 52基因特征在四个队列中通过nCounter检测,在另外两个队列中从微阵列数据提取,检测方法不完全一致。
  • 随访期间仅98例患者(23%)采集了样本,纵向数据有限。
  • 抗纤维化药物反应相关分析仅基于耶鲁队列,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable. Clinical prediction tools are not accurate enough to predict disease outcomes. METHODS: We enrolled patients with IPF diagnosis in a six-cohort study at Yale University (New Haven, CT, USA), Imperial College London (London, UK), University of Chicago (Chicago, IL, USA), University of Pittsburgh (Pittsburgh, PA, USA), University of Freiburg (Freiburg im Breisgau, Germany), and Brigham and Women's Hospital-Harvard Medical School (Boston, MA, USA). Peripheral blood mononuclear cells or whole blood were collected at baseline from 425 participants and from 98 patients (23%) during 4-6 years' follow-up. A 52-gene signature was measured by the nCounter analysis system in four cohorts and extracted from microarray data (GeneChip) in the other two. We used the Scoring Algorithm for Molecular Subphenotypes (SAMS) to classify patients into low-risk or high-risk groups based on the 52-gene signature. We studied mortality with a competing risk model and transplant-free survival with a Cox proportional hazards model. We analysed timecourse data and response to antifibrotic drugs with linear mixed effect models. FINDINGS: The application of SAMS to the 52-gene signature identified two groups of patients with IPF (low-risk and high-risk), with significant differences in mortality or transplant-free survival in each of the six cohorts (hazard ratio [HR] range 2·03-4·37). Pooled data showed similar results for mortality (HR 2·18, 95% CI 1·53-3·09; p<0·0001) or transplant-free survival (2·04, 1·52-2·74; p<0·0001). Adding 52-gene risk profiles to the Gender, Age, and Physiology index significantly improved its mortality predictive accuracy. Temporal changes in SAMS scores were associated with changes in forced vital capacity (FVC) in two cohorts. Untreated patients did not shift their risk profile over time. A simultaneous increase in up score and decrease in down score was predictive of decreased transplant-free survival (3·18, 1·16-8·76; p=0·025) in the Pittsburgh cohort. A simultaneous decrease in up score and increase in down score after initiation of antifibrotic drugs was associated with a significant (p=0·0050) improvement in FVC in the Yale cohort. INTERPRETATION: The peripheral blood 52-gene expression signature is predictive of outcome in patients with IPF. The potential value of the 52-gene signature in predicting response to therapy should be determined in prospective studies. FUNDING: The Pulmonary Fibrosis Foundation, the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, and the National Heart, Lung, and Blood Institute of the US National Institutes of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Herazo-Maya JD, Sun J, Molyneaux PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med. 2017. PMID: 28942086. doi:10.1016/S2213-2600(17)30349-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。